Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer

The Egyptian Heart Journal

Table 1 PQ interval duration before each trastuzumab/trastuzumab emtansine cycle and six months after the last cycle

There were no significant changes in the PQ interval duration, neither in relation to subsequent trastuzumab applications nor 6 six months after the last cycle. Comparable to trastuzumab, no significant changes of the PQ interval were found neither in relation to trastuzumab emtansine cycles, nor six months after the last application of the drug (Table 1)